BRAFi/MEKi in patients with metastatic melanoma: predictive factors of complete response.
A survival benefit was demonstrated by dabrafenib + trametinib for metastatic BRAF-mutated melanoma patients. Best response is a strong prognostic marker for survival. The specific features associated with complete response (CR) were evaluated. A total of 15/66 patients achieved CR. Median size of lesions was 3 cm (range: 0.5-10). Using that value as cut-off, the CR rate was 39.3% in patients with smaller lesions and 10.5% in patients with bigger size (p = 0.006). The clinical features associated with CR were the number of metastatic sites and the largest diameter of the biggest metastatic site. The number of the metastases and the diameter of the largest metastatic site are associated with a higher CR rate.